艾迪药业
(688488)
| 流通市值：72.37亿 | | | 总市值：72.37亿 |
| 流通股本：4.21亿 | | | 总股本：4.21亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 362,484,696.38 | 197,860,545.62 | 417,804,702.67 | 298,875,699.92 |
| 营业收入 | 362,484,696.38 | 197,860,545.62 | 417,804,702.67 | 298,875,699.92 |
| 二、营业总成本 | 347,182,753.38 | 178,441,372.82 | 548,682,156.97 | 378,752,891.66 |
| 营业成本 | 124,761,206.87 | 75,114,905.33 | 188,291,309.03 | 141,037,593.52 |
| 税金及附加 | 5,354,740.8 | 2,530,698.33 | 5,610,704.34 | 3,763,380.3 |
| 销售费用 | 124,403,595.73 | 57,867,148.6 | 155,032,579.3 | 90,535,046.51 |
| 管理费用 | 44,200,667.21 | 23,678,257.46 | 96,913,688.51 | 69,857,158.37 |
| 研发费用 | 41,599,388.41 | 15,711,444.19 | 89,887,129.01 | 64,015,925.06 |
| 财务费用 | 6,863,154.37 | 3,538,918.91 | 12,946,746.78 | 9,543,787.9 |
| 其中:利息费用 | 8,088,243.91 | 4,246,314.54 | 15,360,254.21 | 11,129,579.68 |
| 其中:利息收入 | 1,307,547.53 | 714,034.64 | 2,523,349.69 | 1,746,807.36 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 14,218,294.32 | 9,262,691.53 | 10,763,010.03 | 23,348,835.85 |
| 加:投资收益 | -568,771.59 | -225,518.4 | 6,962,716.68 | 7,562,596.88 |
| 资产处置收益 | 99,170.37 | - | - | - |
| 资产减值损失(新) | -2,896,425.23 | - | -65,199,313.37 | -45,476,095 |
| 信用减值损失(新) | 479,142.61 | 1,220,693.58 | 2,591,374.41 | 3,099,066 |
| 其他收益 | 5,471,023.85 | 2,150,673.88 | 11,294,290.52 | 14,010,402.71 |
| 营业利润平衡项目 | -0.01 | 0 | 0 | 0 |
| 四、营业利润 | 32,104,377.32 | 31,827,713.39 | -164,465,376.03 | -77,332,385.3 |
| 加:营业外收入 | 1,267,015.19 | 101,943.16 | 408,648.41 | 133,577.6 |
| 减:营业外支出 | 804,170.28 | 368,942.92 | 1,940,294.69 | 1,301,018.98 |
| 五、利润总额 | 32,567,222.23 | 31,560,713.63 | -165,997,022.31 | -78,499,826.68 |
| 减:所得税费用 | 6,077,751.58 | 5,950,734.51 | -27,161,932.61 | -16,775,489.52 |
| 六、净利润 | 26,489,470.65 | 25,609,979.12 | -138,835,089.7 | -61,724,337.16 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 26,489,470.65 | 25,609,979.12 | -138,835,089.7 | -61,724,337.16 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 9,190,954.53 | 15,581,976.25 | -141,204,293.98 | -60,941,628.92 |
| 少数股东损益 | 17,298,516.12 | 10,028,002.87 | 2,369,204.28 | -782,708.24 |
| 扣除非经常损益后的净利润 | -5,112,714.15 | 7,399,659.11 | -148,445,417.91 | -83,560,883.3 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | 0.04 | -0.34 | -0.14 |
| (二)稀释每股收益 | 0.02 | 0.04 | -0.34 | -0.14 |
| 九、综合收益总额 | 26,489,470.65 | 25,609,979.12 | -138,835,089.7 | -61,724,337.16 |
| 归属于母公司股东的综合收益总额 | 9,190,954.53 | 15,581,976.25 | -141,204,293.98 | -60,941,628.92 |
| 归属于少数股东的综合收益总额 | 17,298,516.12 | 10,028,002.87 | 2,369,204.28 | -782,708.24 |
| 公告日期 | 2025-08-29 | 2025-04-30 | 2025-04-30 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |